Pulmatrix (PULM) Filings

8-K

Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

8 Oct 24

8-K

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

13 Aug 24

8-K

Departure of Directors or Certain Officers

19 Jul 24

EFFECT

Notice of effectiveness

31 May 24

8-K

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

29 May 24

S-3

Shelf registration

17 May 24

8-K

Regulation FD Disclosure

15 May 24

8-K

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

10 May 24

424B3

Prospectus supplement

28 Mar 24

8-K

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

28 Mar 24

8-K

Departure of Directors or Certain Officers

13 Mar 24

8-K

Regulation FD Disclosure

4 Mar 24

8-K

Entry into a Material Definitive Agreement

8 Jan 24

8-K

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

9 Nov 23

8-K

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

10 Aug 23

8-K

Submission of Matters to a Vote of Security Holders

13 Jul 23

8-K

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

11 Jul 23

ARS

2022 FY

Annual report to shareholders

2 Jun 23

8-K

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

12 May 23

8-K

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

30 Mar 23

8-K

Regulation FD Disclosure

6 Feb 23

8-K

Regulation FD Disclosure

3 Feb 23

8-K

Regulation FD Disclosure

25 Jan 23

8-K

Regulation FD Disclosure

11 Jan 23

8-K

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

4 Jan 23

8-K

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

14 Nov 22

8-K

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

26 Sep 22

8-K

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

10 Aug 22

424B3

Prospectus supplement

9 Aug 22

8-K

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

12 Jul 22

SC 13G/A

SABBY MANAGEMENT, LLC

2 Jan 24

SC 13G/A

INTRACOASTAL CAPITAL, LLC

8 Feb 23

4

Michelle Siegert

30 Jan 23

4

Margaret Wasilewski

30 Jan 23

4

Teofilo David Raad

30 Jan 23

4

Todd Bazemore

30 Jan 23

4

Michael J Higgins

30 Jan 23

4

Christopher Cabell

30 Jan 23

4

Anand Varadan

30 Jan 23

4

Richard P. Batycky

30 Jan 23

SC 13G/A

SABBY MANAGEMENT, LLC

10 Jan 23

3

Peter Ludlum

19 Apr 22

4

Margaret Wasilewski

3 Mar 22

3

Margaret Wasilewski

3 Mar 22

SC 13G/A

CVI Investments, Inc.

14 Feb 22

SC 13G/A

INTRACOASTAL CAPITAL, LLC

11 Feb 22

SC 13G/A

RENAISSANCE TECHNOLOGIES LLC

10 Feb 22

4

Michael J Higgins

31 Jan 22

4

Richard P. Batycky

31 Jan 22

4

Christopher Cabell

31 Jan 22

4

Todd Bazemore

28 Jan 22

4

Anand Varadan

28 Jan 22

4

Michelle Siegert

28 Jan 22

4

Teofilo David Raad

28 Jan 22

SC 13G/A

SABBY MANAGEMENT, LLC

5 Jan 22

4

Anand Varadan

28 Jul 21

3

Anand Varadan

28 Jul 21

SC 13D

FiveT Investment Management Ltd

25 Feb 21

SC 13G

CVI Investments, Inc.

24 Feb 21

SC 13G/A

CVI Investments, Inc.

16 Feb 21

SC 13G

RENAISSANCE TECHNOLOGIES LLC

10 Feb 21

4

Amit Munshi

1 Feb 21

4

Mark T Iwicki

1 Feb 21

4

Christopher Cabell

1 Feb 21

4

Michelle Siegert

1 Feb 21

4

Todd Bazemore

1 Feb 21

4

Michael J Higgins

1 Feb 21

4

Teofilo David Raad

1 Feb 21

4

Richard P. Batycky

1 Feb 21

SC 13G/A

INTRACOASTAL CAPITAL, LLC

29 Jan 21